• Profile
Close

Glomerular filtration rate change during chronic hepatitis C treatment with sofosbuvir/ledipasvir in HCV/HIV coinfected patients treated with tenofovir and a boosted protease inhibitor: An observational prospective study

BMC Infectious Diseases Aug 09, 2018

Soeiro CASP, et al. - Hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfected patients receiving HCV treatment with sofosbuvir/ledipasvir (SOF/LDV) were evaluated for glomerular filtration rate (eGFR) change according to antiretroviral treatment (ARV). Based on ARV regimen, researchers categorized patients into three groups: non tenofovir (TDF), non-boosted TDF, and TDF plus boosted protease inhibitors. All study groups displayed a significant decrease in eGFR during treatment. Following SOF/LDV discontinuation, this decrease was small and reversible. No increased renal toxicity was observed in association with TDF.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay